ESMO 2020: Dr. Peter Fasching: Pooled analysis of PRO of QOL in M2, M3 and M7 Dr. Peter Fasching speaking on "Pooled analysis of PRO of QOL in M2, M3 and M7" ESMO 00:03:30
Key takeaways from NEJM 12/2019 ML3 OS data Dr. Peter Fasching is discussing the key takeaways from NEJM 12/2019 ML3 OS data. Kisqali Channel 00:01:35
ESMO 2020: Dr. Sara Hurvitz: Ribociclib and resistance to prior ET in the M3 and M7 Dr. Sara Hurvitz is speaking on "Ribociclib and resistance to prior ET in the M3 and M7". ESMO 00:02:49
ESMO 2020: Dr. Michelino De Laurentiis: Ribociclib dose reduction on OS in M3 and M7 Dr. Michelino De Laurentiis is speaking on "Ribociclib dose reduction on OS in M3 and M7." ESMO 00:03:49
Should PFS outcomes drive treatment decisions in aBC when statistical significant improvement in OS is shown? Should PFS outcomes drive treatment decisions in aBC when statistical significant improvement in OS is shown? Kisqali Channel 00:07:05
How clinical relevance is assessed in randomized clinical trials? How clinical relevance is assessed in randomized clinical trials? Kisqali Channel 00:05:42
